136 related articles for article (PubMed ID: 11054987)
21. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
22. Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution.
Brion A; Legrand F; Larosa F; Schillinger F; Garnache-Ottou F; Helias P; Fontan J; Heczko M; Delaby P; Daguindau E; Vuillier J; Chauchet A; Deconinck E
Invest New Drugs; 2012 Aug; 30(4):1697-702. PubMed ID: 21229289
[TBL] [Abstract][Full Text] [Related]
23. Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium.
Bleyer WA
Clin Cancer Res; 1999 Nov; 5(11):3349-51. PubMed ID: 10589743
[No Abstract] [Full Text] [Related]
24. Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience.
Gaviani P; Corsini E; Salmaggi A; Lamperti E; Botturi A; Erbetta A; Milanesi I; Legnani F; Pollo B; Silvani A
Neurol Sci; 2013 Dec; 34(12):2151-7. PubMed ID: 23525755
[TBL] [Abstract][Full Text] [Related]
25. Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.
Kripp M; Hofheinz RD
Int J Nanomedicine; 2008; 3(4):397-401. PubMed ID: 19337408
[TBL] [Abstract][Full Text] [Related]
26. [Rationale for the use of liposomal cytarabine in meningeal carcinomatosis].
Boiardi A
Tumori; 2007; 93(3):suppl 1-3. PubMed ID: 17679478
[No Abstract] [Full Text] [Related]
27. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
[TBL] [Abstract][Full Text] [Related]
28. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine.
Bohn JP; Reinstadler V; Pall G; Stockhammer G; Steurer M; Oberacher H; Wolf D
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):845-851. PubMed ID: 31435852
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of liposomal cytarabine in neoplastic meningitis].
Rudà R; Leoncini B; Laguzzi E; Trevisan E; Guarneri D; Bertetto O; Soffietti R
Tumori; 2007; 93(3):suppl 4-5. PubMed ID: 17679479
[No Abstract] [Full Text] [Related]
31. Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy.
Kim S; Kim DJ; Geyer MA; Howell SB
Cancer Res; 1987 Aug; 47(15):3935-7. PubMed ID: 3607740
[TBL] [Abstract][Full Text] [Related]
32. Multivesicular liposomes. Sustained release of the antimetabolite cytarabine in the eye.
Assil KK; Weinreb RN
Arch Ophthalmol; 1987 Mar; 105(3):400-3. PubMed ID: 3827719
[TBL] [Abstract][Full Text] [Related]
33. Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine.
Salehi B; Selamoglu Z; S Mileski K; Pezzani R; Redaelli M; Cho WC; Kobarfard F; Rajabi S; Martorell M; Kumar P; Martins N; Subhra Santra T; Sharifi-Rad J
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31771220
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.
Garcia-Marco JA; Panizo C; Garcia ES; Deben G; Alvarez-Larran A; Barca EG; Sancho JM; Penarrubia MJ; Garcia-Cerecedo T; Garcia Vela JA
Cancer; 2009 May; 115(9):1892-8. PubMed ID: 19235254
[TBL] [Abstract][Full Text] [Related]
35. Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors.
Lassaletta A; Lopez-Ibor B; Mateos E; Gonzalez-Vicent M; Perez-Martinez A; Sevilla J; Diaz MA; Madero L
J Neurooncol; 2009 Oct; 95(1):65-69. PubMed ID: 19381444
[TBL] [Abstract][Full Text] [Related]
36. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments.
Benesch M; Urban C
Expert Opin Pharmacother; 2008 Feb; 9(2):301-9. PubMed ID: 18201152
[TBL] [Abstract][Full Text] [Related]
37. Development of cytarabine prodrugs and delivery systems for leukemia treatment.
Chhikara BS; Parang K
Expert Opin Drug Deliv; 2010 Dec; 7(12):1399-414. PubMed ID: 20964588
[TBL] [Abstract][Full Text] [Related]
38. Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and in vitro release.
Ruckmani K; Jayakar B; Ghosal SK
Drug Dev Ind Pharm; 2000 Feb; 26(2):217-22. PubMed ID: 10697760
[TBL] [Abstract][Full Text] [Related]
39. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
40. [Experience with the intrathecal use of liposomal cytarabine at the Besta Institute].
Silvani A
Tumori; 2007; 93(3):suppl 6-8. PubMed ID: 17679480
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
